What Happened?
On July 30, 2025, Eubiologics received domestic approval for its typhoid vaccine, EuTyphiC Multidose (for export). This milestone comes approximately nine months after the application was submitted in October 2024 and follows successful Phase 3 clinical trials in Africa.
Why is This Approval Important?
This approval is a critical stepping stone towards WHO prequalification (PQ) and potential vaccine supply to UNICEF. UNICEF supply could translate into significant revenue growth, offsetting the decline in cholera vaccine sales and driving the company’s long-term growth. It is also expected to positively influence the development of other vaccine pipelines.
What’s the Outlook?
- Positive Outlook: WHO PQ approval could lead to large-scale exports through UNICEF, increasing revenue and profitability, raising the company’s value, and providing momentum for stock price appreciation.
- Negative Outlook & Risk Factors: Potential failure to obtain WHO PQ approval, intensified competition in the global vaccine market, risks associated with raw material prices and exchange rate fluctuations, and changes in market demand for typhoid vaccines.
- Market Conditions: Increased volatility in KRW/USD and KRW/EUR exchange rates, rising interest rates, and fluctuating raw material prices require careful consideration.
What Should Investors Do?
While Eubiologics holds strong long-term growth potential, investors should continuously monitor WHO PQ progress, the company’s global market entry strategy, and external market changes, adjusting their investment strategies accordingly. A long-term investment approach that isn’t swayed by short-term stock fluctuations is recommended.